000134799 001__ 134799
000134799 005__ 20240229105041.0
000134799 0247_ $$2doi$$a10.1007/s00259-018-3965-8
000134799 0247_ $$2pmid$$apmid:29497802
000134799 0247_ $$2ISSN$$a0340-6997
000134799 0247_ $$2ISSN$$a1432-105X
000134799 0247_ $$2ISSN$$a1619-7070
000134799 0247_ $$2ISSN$$a1619-7089
000134799 0247_ $$2altmetric$$aaltmetric:33890036
000134799 037__ $$aDKFZ-2018-00592
000134799 041__ $$aeng
000134799 082__ $$a610
000134799 1001_ $$00000-0002-4492-4243$$aAfshar-Oromieh, Ali$$b0
000134799 245__ $$aTracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.
000134799 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2018
000134799 3367_ $$2DRIVER$$aarticle
000134799 3367_ $$2DataCite$$aOutput Types/Journal article
000134799 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565682851_349
000134799 3367_ $$2BibTeX$$aARTICLE
000134799 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134799 3367_ $$00$$2EndNote$$aJournal Article
000134799 520__ $$aSince the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequently observed mediastinal lymph nodes (LN) showing tracer uptake despite being classified as benign. The aim of this evaluation was to further analyze such LN.Two patient groups with biphasic 68Ga-PSMA-11 PET/CT at 1 h and 3 h p.i. were included in this retrospective evaluation. Group A (n = 38) included patients without LN metastases, and group B (n = 43) patients with LN metastases of PC. SUV of mediastinal/paraaortal LN of group A (n = 100) were compared to SUV of LN metastases of group B (n = 91). Additionally, 22 randomly selected mediastinal and paraaortal LN of patients without PC were immunohistochemically (IHC) analyzed for PSMA expression.In group A, 7/38 patients (18.4%) presented with at least one PSMA-positive mediastinal LN at 1 h p.i. and 3/38 (7.9%) positive LN at 3 h p.i. with a SUVmax of 2.3 ± 0.7 at 1 h p.i. (2.0 ± 0.7 at 3 h p.i.). A total of 11 PSMA-positive mediastinal/paraaortal LN were detected in nine patients considering both imaging timing points. SUVmax of LN-metastases was 12.5 ± 13.2 at 1 h p.i. (15.8 ± 17.0 at 3 h p.i.). SUVmax increased clearly (> 10%) between 1 h and 3 h p.i. in 76.9% of the LN metastases, and decreased significantly in 72.7% of the mediastinal/paraaortal LN. By IHC, PSMA-expression was observed in intranodal vascular endothelia of all investigated LN groups and to differing degrees within germinal centers of 15/22 of them (68.1%). Expression was stronger in mediastinal nodes (p = 0.038) and when follicular hyperplasia was present (p = 0.050).PSMA-positive mediastinal/paraaortal benign LN were visible in a notable proportion of patients. PSMA-positivity on the histopathological level was associated with the activation state of the LN. However, in contrast to LN metastases of PC, they presented with significantly lower uptake, which, in addition, usually decreased over time.
000134799 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000134799 588__ $$aDataset connected to CrossRef, PubMed,
000134799 7001_ $$aSattler, Lars Peter$$b1
000134799 7001_ $$aSteiger, Katja$$b2
000134799 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b3$$udkfz
000134799 7001_ $$ada Cunha, Marcelo Livorsi$$b4
000134799 7001_ $$aMier, Walter$$b5
000134799 7001_ $$0P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aNeels, Oliver$$b6$$udkfz
000134799 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b7$$udkfz
000134799 7001_ $$0P:(DE-HGF)0$$aWeichert, Wilko$$b8
000134799 7001_ $$aHaberkorn, Uwe$$b9
000134799 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-018-3965-8$$gVol. 45, no. 7, p. 1179 - 1187$$n7$$p1179 - 1187$$tEuropean journal of nuclear medicine and molecular imaging$$v45$$x1619-7089$$y2018
000134799 909CO $$ooai:inrepo02.dkfz.de:134799$$pVDB
000134799 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134799 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000134799 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000134799 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000134799 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000134799 9141_ $$y2018
000134799 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134799 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134799 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134799 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000134799 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000134799 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000134799 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134799 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000134799 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134799 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134799 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134799 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000134799 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000134799 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000134799 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x1
000134799 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000134799 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x3
000134799 980__ $$ajournal
000134799 980__ $$aVDB
000134799 980__ $$aI:(DE-He78)C060-20160331
000134799 980__ $$aI:(DE-He78)E030-20160331
000134799 980__ $$aI:(DE-He78)L101-20160331
000134799 980__ $$aI:(DE-He78)L701-20160331
000134799 980__ $$aUNRESTRICTED